{"id":"W1990925084","doi":"10.1016/s1473-3099(13)70257-3","title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Raltegravir; Dolutegravir; Medicine; Emtricitabine; Tolerability; Abacavir; Lamivudine; Population; Internal medicine; Clinical trial; Integrase inhibitor; Human immunodeficiency virus (HIV); Viral load; Adverse effect; Antiretroviral therapy; Virology; Virus; Chronic hepatitis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004595702,0.0007033093,0.001398527,0.000343641,0.0003656985,0.0002390876,0.0002680441,0.000178118,0.0001146447],"category_scores_gemma":[0.000303185,0.0004475566,0.0003028023,0.0008682173,0.0002134199,0.0004811751,0.0001248229,0.0006749435,0.0005457971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005095578,"about_ca_system_score_gemma":0.0004340404,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02033013,"about_ca_topic_score_gemma":0.004597378,"domain_scores_codex":[0.996249,0.0003714209,0.0008902238,0.0009361354,0.0007393389,0.0008138836],"domain_scores_gemma":[0.9971546,0.0007322547,0.0004470898,0.001058217,0.0002477624,0.0003600952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.537554,0.002640698,0.4548552,0.00003697441,0.0006221171,0.0001016184,0.001583901,0.0000394688,0.00001545363,0.00000715132,0.001143532,0.001399897],"study_design_scores_gemma":[0.6238386,0.003375047,0.3700543,0.0002903759,0.0008147429,0.000005809115,0.0005060954,0.0001067835,0.00005810457,0.00004628395,0.0004905346,0.0004133289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856567,0.0001526952,0.00003143793,0.0009324825,0.0007174282,0.008971809,0.0001468656,0.0004639697,0.002926548],"genre_scores_gemma":[0.9947482,0.0002867967,0.00007860176,0.0001517081,0.001376443,0.002155621,0.0003952209,0.00007575227,0.0007316498],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08628462,"threshold_uncertainty_score":0.9997976,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03039458746160299,"score_gpt":0.2889750520106316,"score_spread":0.2585804645490286,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}